Terms: = Germ cell tumor AND WWTR1, ENSG00000018408, 25937, Q9GZV5, DKFZP586I1419
9 results:
1. Identification of angiogenesis-related genes signature for predicting survival and its regulatory network in glioblastoma.
Wan Z; Zuo X; Wang S; Zhou L; Wen X; Yao Y; Song J; Gu J; Wang Z; Liu R; Luo C
Cancer Med; 2023 Aug; 12(16):17445-17467. PubMed ID: 37434432
[TBL] [Abstract] [Full Text] [Related]
2. YAP1 and wwtr1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma.
Frost TC; Gartin AK; Liu M; Cheng J; Dharaneeswaran H; Keskin DB; Wu CJ; Giobbie-Hurder A; Thakuria M; DeCaprio JA
J Clin Invest; 2023 Mar; 133(5):. PubMed ID: 36719743
[TBL] [Abstract] [Full Text] [Related]
3. SOX2 maintains the stemness of retinoblastoma stem-like cells through Hippo/YAP signaling pathway.
Zhao N; Zhou L; Lu Q; Wang S; Sun Y; Ding Y; Liu M; He H; Lang T
Exp Eye Res; 2022 Jan; 214():108887. PubMed ID: 34890603
[TBL] [Abstract] [Full Text] [Related]
4. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.
Yang KC; Kalloger SE; Aird JJ; Lee MKC; Rushton C; Mungall KL; Mungall AJ; Gao D; Chow C; Xu J; Karasinska JM; Colborne S; Jones SJM; Schrader J; Morin RD; Loree JM; Marra MA; Renouf DJ; Morin GB; Schaeffer DF; Gorski SM
Cell Rep; 2021 Oct; 37(2):109817. PubMed ID: 34644566
[TBL] [Abstract] [Full Text] [Related]
5. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity.
Pearson JD; Huang K; Pacal M; McCurdy SR; Lu S; Aubry A; Yu T; Wadosky KM; Zhang L; Wang T; Gregorieff A; Ahmad M; Dimaras H; Langille E; Cole SPC; Monnier PP; Lok BH; Tsao MS; Akeno N; Schramek D; Wikenheiser-Brokamp KA; Knudsen ES; Witkiewicz AK; Wrana JL; Goodrich DW; Bremner R
Cancer Cell; 2021 Aug; 39(8):1115-1134.e12. PubMed ID: 34270926
[TBL] [Abstract] [Full Text] [Related]
6. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract] [Full Text] [Related]
7. YAP/TAZ: Drivers of tumor Growth, Metastasis, and Resistance to Therapy.
Thompson BJ
Bioessays; 2020 May; 42(5):e1900162. PubMed ID: 32128850
[TBL] [Abstract] [Full Text] [Related]
8. Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas.
Escoll M; Lastra D; Pajares M; Robledinos-Antón N; Rojo AI; Fernández-Ginés R; Mendiola M; Martínez-Marín V; Esteban I; López-Larrubia P; Gargini R; Cuadrado A
Redox Biol; 2020 Feb; 30():101425. PubMed ID: 31918259
[TBL] [Abstract] [Full Text] [Related]
9. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract] [Full Text] [Related]
